Galena Biopharma, Inc.

  • Four Biotechnology Stocks Ready To Rise

    By Craig Keolanui - July 18, 2013 | Tickers: ACUR, ARNA, GALE, ONTY

    As the market advances and many biotechnology issues along with it, diamonds in the rough are being increasingly hard to come by. Finding companies with products that have reached market, cash on hand to advance products in the pipeline or even multiple products that have potential is not an easy task. The following four companies have some of these ingredients to offer investors, but have essentially flown under the radar more »

  • Should You Buy the Hype Surrounding This Product Launch?

    By Sherrie Stone - July 1, 2013 | Tickers: AMRN, ARIA, GALE, VVUS

    While the analysis of peak sales and potential patient populations may be appealing to most, it costs a great deal of money to launch a new product with success. In the case of Galena Biopharma (NASDAQ: GALE), the company doesn’t have the cash, but touts tremendous sales potential, so might the company succeed anyway?

    The reality of launching drugs in healthcare

    I would like to share with you something more »

  • Good And Bad Breast Cancer Drugs

    By Sherrie Stone - June 14, 2013 | Tickers: CLDX, GALE, RHHBY

    With more than 230,000 women diagnosed with breast cancer in the U.S. annually – and Roche’s (NASDAQOTH: RHHBY) Herceptin producing annual sales of more than $5 billion – the potential for breast cancer drugs is enormous. While there are many companies developing drugs to treat the disease, there are two specifically with late-phase drugs that have been favorites in the market.

    A breakthrough drug

    Since the start of 2012 more »

  • 2 Drugs With Acquisition Potential

    By Mohsin Saeed - June 5, 2013 | Tickers: AZN, GALE, ONCY

    Big pharmaceutical players, known as Big Pharma, depend on patents to fend of generic threats to their blockbuster drugs. So when a patent expires, cheaper generic products flood the market. The sales of the premium drug take a nose dive once similar compounds are available at cheaper rates.

    Therefore, it is imperative for big-pharmaceutical players to continue the hunt for new candidates. In this lies the enormous potential of small more »

  • Galena: Improving Cancer Vaccines for the Future

    By Terry Chrisomalis - May 7, 2013 | Tickers: DNDN, GALE, VICL

    There are some vaccine companies that have game changing technologies to target different types of cancer. One such company looking to improve upon cancer vaccines, is a small cap biotech company known as Galena Biopharma (NASDAQ: GALE). The company has many types of vaccine candidates in its pipeline, and is currently in one phase 3 study for breast cancer. The vaccine candidate to treat breast cancer is called NeuVax. 

    The more »

  • 2 Biotechs To Avoid, 1 To Buy

    By Mohsin Saeed - May 3, 2013 | Tickers: AVEO, GALE, ITMN

    The earnings season is in full swing and investors are flooded with fundamental information to reassess their investments. While fundamental information should be a basic component for any investment decision, it becomes irrelevant in the biotechnology industry. The companies in this sector are usually involved in development of candidates without much topline or bottom line information. The trades by institutions and insiders are a more effective way for potential investors more »

  • Galena Improving Cancer Vaccines For The Future

    By Terry Chrisomalis - May 1, 2013 | Tickers: DNDN, GALE, VICL

    There are some vaccine companies that have game changing technologies to target different types of cancer. One such company looking to improve upon cancer vaccines, is a small cap biotech company known as Galena Biopharma (NASDAQ: GALE). The company has many types of vaccine candidates in its pipeline, and is currently in one phase 3 study for Breast Cancer. The vaccine candidate to treat breast cancer is called NeuVax. 

    The more »

  • 2 Biopharmaceutical Companies Worth Buying

    By Mohsin Saeed - April 29, 2013 | Tickers: AZN, GALE, GILD

    The biotechnology industry had a good time last year and the market expects the trend to continue in 2013 as well. As the chart below shows, the AMEX biotechnology index has outperformed the S&P 500 index by a mile in the last one year. A major factor behind this stellar performance has been the large number of drug approvals by the FDA.

    I believe that the sector will continue more »

  • Three Biotech Giants to Look For

    By Abir Karmakar - April 3, 2013 | Tickers: ACHN, BIOL, GALE

    In the world of biotech investing, there are many companies to choose from. When the market is on a riding stride, investment in more speculative stocks that have inflated valuations can get tough. There still may be potential for several biotech stocks that are immune to downturn or sidewise movements in the market. Galena Biopharma  (NASDAQ: GALE), Biolase (NASDAQ: BIOL), and Achillion Pharmaceuticals (NASDAQ: ACHN) are the three stocks that more »

  • 2 Biopharmaceuticals With Huge Upside Potential

    By Mohsin Saeed - March 20, 2013 | Tickers: GALE, ONCY, TEVA

    The Biopharmaceutical industry was one of the most profitable last year. A number of companies have appreciated to sky high valuations and returned investors a lot of money. While this price appreciation is good news for investors that are already invested, it leaves little room for new investors to make money. There are still a few biopharmaceuticals available at cheap valuations, however. I believe Galena BioPharma (NASDAQ: GALE) and Oncolytics more »

  • 100% Upside on these Bio-techs

    By Mohsin Saeed - January 31, 2013 | Tickers: GALE, MNKD, TEVA

    The approval of a drug candidate is one of the most important events for any biopharmaceutical company, and the approval event becomes even more important for biopharmaceuticals with a limited pipeline. This is because the valuations of the company are strongly affected by the approval or rejection of its candidate. The following two companies have major candidates nearing the end of Phase III clinical trials, and these drugs can significantly more »

  • Five Amazing Biotech Picks with Futuristic Technology

    By Streetwise Reports - January 29, 2013 | Tickers: ARIA, ASTX, GALE, SRPT

    Michael King is looking for the monoclonal antibodies of tomorrow. When I first spoke to him 15 or more years ago, King was talking up Immunex, which would later be taken out by Amgen for $16 billion for its anti-tumor necrosis factor (anti-TNF) fusion protein Enbrel (etanercept) to treat rheumatoid arthritis. Today Amgen’s (via Immunex) Enbrel and the anti-TNF monoclonal antibodies that would follow-- Johnson & Johnson’s Remicade (infliximab more »

  • A Bio-Pharmaceutical With Huge Upside Potential

    By Mohsin Saeed - January 7, 2013 | Tickers: GALE, PFE, RHHBY, TEVA

    Galena BioPharma (NASDAQ: GALE) has shared excellent clinical trial results for NeuVax. The stock is trading well below analysts’ consensus mean target price and, I believe, offers a huge return to investors.

    Galena has already attracted two Big Pharma partners, namely Roche and Teva Pharmaceuticals (NYSE: TEVA). I believe that the interest of big pharma warrants much higher valuations for this stock. The company has the potential to be acquired more »

  • Pinktober Biotechs

    By AnnaLisa Kraft - October 13, 2012 | Tickers: CELG, GALE, IMGN

    Pinktober is here and all things breast cancer awareness related. If you are a breast cancer survivor I understand it can be painful to be reminded at every turn but just remember it means progress for the women after you. If you know at least eight females, one will likely be diagnosed with breast cancer in her lifetime. And there are some biotechs making advances in the field, Celgene (NASDAQ: CELGmore »)

  • A Fool's Look at Galena Biopharma's Rally

    By Natalie Dawahare - September 13, 2012 | Tickers: ARNA, GALE, PCYC, REGN

    Chances are, you’re aware of the astonishing gains that some of biotech’s darlings have produced in the first nine months of 2012. Perhaps it’s Arena Pharmaceuticals’ (NASDAQ: ARNA) 350% gain; maybe its Pharmacyclics’ (NASDAQ: PCYC) 330% return, or even Regeneron’s (NASDAQ: REGN) 170% return in 2012 that has caught your attention. But most likely, it hasn’t been Galena Biopharma (NASDAQ: GALE), a $125 million company more »